This article is Part VI of a review series covering all the initial public offerings for the biotech and pharmaceutical industries in 2021. Pt. I and Pt. II provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Pt. III and Pt. IV provided a deep dive into the 2021 IPOs for oncology-focused companies, while P.t V provided a deep dive into the 2021 IPOs for neurology-focused companies.
This short article takes a deeper look into the 2021 IPOs for small molecule and biotechnology-based therapeutics being developed by immunology-focused companies, including:
- S1P1 modulators for inflammatory diseases
- An IL-17 antagonist from DEL screening
- An immune cell-based therapy
- An anti-TL1A antibody
- And more
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
